CPHI
CHINA PHARMA HOLDINGS, INC.
Next earnings ≈ Aug 13, 2026 · est. from filing cadence
$0.64
▲ +1.70%$0.64▼ -62.20%
over 1Y
L $0.52EODHDH $2.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.7%
1W-15.8%
1M-18.0%
3M-3.9%
YTD-49.2%
1Y-63.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity 0.36x); but revenue declined -8.5% YoY.
Revenue (FY2025) $4.14M · FY2025
CHINA PHARMA HOLDINGS, INC. shows $4.14M in FY2025 revenue (-8.5% YoY), a -76.9% net margin, and -14.0% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $9.64M | $8.10M | $7.01M | $4.53M | $4.14M |
| Gross profit | $349K | -$494K | -$281K | -$1.99M | -$132K |
| Operating income | -$2.86M | -$3.55M | -$2.75M | -$4.59M | -$3.24M |
| Net income | -$3.40M | -$3.97M | -$3.08M | -$4.74M | -$3.19M |
| Diluted EPS | -$0.74 | -$3.78 | -$0.91 | -$2.71 | -$0.74 |
| Net margin | -35.3% | -49.0% | -43.9% | -104.6% | -76.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$32.1M
EV / EBITDA—
EV / Sales7.7
EV / FCF360.5
P / FCF289.3
PEG (trailing)—
Earnings yield-12.4%
FCF yield0.3%
Quality & risk
ROIC (est.)-8.7%
Free cash flow$88.9K
Total debt$6.68M
Net cash-$6.33M
Altman Z-Score-0.67 distress
Piotroski F-Score5/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+24.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-04-01). Worth a closer look.
Recent filings
all on EDGAR ↗10-QPeriod ending 2026-03-312026-05-15open ↗10-KPeriod ending 2025-12-312026-04-01open ↗NT 10-KPeriod ending 2025-12-312026-04-01open ↗8-KPeriod ending 2026-02-262026-03-03open ↗8-KPeriod ending 2026-02-052026-02-10open ↗8-KPeriod ending 2025-12-302026-01-06open ↗8-KPeriod ending 2025-12-222025-12-23open ↗8-KPeriod ending 2025-12-042025-12-10open ↗DEF 14APeriod ending 2025-12-302025-11-14open ↗10-QPeriod ending 2025-09-302025-11-12open ↗PRE 14APeriod ending 2025-11-042025-11-04open ↗10-QPeriod ending 2025-06-302025-08-14open ↗
Frequently asked
- Is CHINA PHARMA HOLDINGS, INC. (CPHI) a buy?
- CPHI currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.36x); but revenue declined -8.5% YoY.
- What is CHINA PHARMA HOLDINGS, INC.'s quality score?
- CPHI scores 49.74509803921568/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001106644, latest 10-Q filed 2026-05-15) · EODHD · as of 6/22/2026, 11:37:33 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.